Celgene Reports First Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Celgene (CELG) Q1 'Strong' in Seasonally Weak Quarter, BMO Capital Says
April 30, 2015 2:57 PM EDTBMO Capital analyst Jim Birchenough reiterated his Outperform rating and $163 price target on Celgene (NASDAQ: CELG) following Q1 result which he called "solid" despite seasonal headwinds.
Birchenough commented, "We are reiterating our Outperform rating on the shares of CELG following review of 1Q15... More
Celgene (CELG) Tops Q1 EPS by 1c
April 30, 2015 7:31 AM EDTCelgene (NASDAQ: CELG) reported Q1 EPS of $1.07, $0.01 better than the analyst estimate of $1.06. Revenue for the quarter came in at $2.08 billion versus the consensus estimate of $2.11 billion.
Product and Pipeline Updates
Hematology
REVLIMID®: In February, the U.S. Food and Drug Administration expanded the approved indication for REVLIMID® to include the treatment of patients with newly diagnosed multiple myeloma (NDMM), in combination with dexamethasone. Also in February, the European Commission (EC) approved REVLIMID® for the treatment of adult patients with previously untreated multiple... More
